 Glucagon-Like Peptide-1 Receptor
"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).
| Descriptor ID |
D000067757
|
| MeSH Number(s) |
D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
|
| Concept/Terms |
Glucagon-Like Peptide-1 Receptor- Glucagon-Like Peptide-1 Receptor
- Glucagon Like Peptide 1 Receptor
- Peptide-1 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-1
- GLP-1R Receptor
- GLP 1R Receptor
- Receptor, GLP-1R
- GLP1R Protein
- Protein, GLP1R
- GLP-1 Receptor
- GLP 1 Receptor
- Receptor, GLP-1
- GLP1R Receptor
- Receptor, GLP1R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 7 | 7 | | 2015 | 0 | 2 | 2 | | 2016 | 1 | 0 | 1 | | 2017 | 3 | 1 | 4 | | 2018 | 1 | 3 | 4 | | 2019 | 1 | 2 | 3 | | 2020 | 2 | 4 | 6 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 2 | 1 | 3 | | 2026 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
Zalucha EM, Hutch CR, Bethea M, Cook TM, Unadkat A, Wells KL, Kim KS, Maerz B, Lehrke M, Singer K, Sandoval DA. The Role of Pancreatic Preproglucagon in Regulating Local Inflammation in Mice. Cells. 2026 Mar 06; 15(5).
-
Chao AM, Gilden A, Wadden TA. Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. PLoS Med. 2026 Jan; 23(1):e1004871.
-
Bethea M, Cook T, Mommandi M, McClennan A, Martin A, Hendrix JJ, Hutch CR, Lewis A, Seeley RJ, Fenselau H, da Silva Teixeria S, Sandoval DA. Weight loss reverses obesity-associated impairments in acute gastrointestinal stretch-induced suppression of food intake and glucose homeostasis. Mol Metab. 2025 Dec; 102:102260.
-
Harrall KK, Glueck DH, Lange LA, Litkowski EM, Vanderlinden LA, Konigsberg IR, Cree MG, Perng W, Dabelea D. GLP-1R Gene Polymorphisms and Metabolic Traits During Childhood and Adolescence: The EPOCH Study. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e3031-e3040.
-
Harrall KK, Glueck DH, Lange LA, Litkowski EM, Vanderlinden LA, Konigsberg IR, Cree MG, Perng W, Dabelea D. GLP-1R Polymorphisms Modify the Relationship Between Exposure to Gestational Diabetes Mellitus and Offspring BMI Growth: The EPOCH Study. Diabetes Care. 2025 Jul 01; 48(7):1280-1287.
-
Akhverdyan N, Wieland A, Sullivan S, Lindsay M, Swartwood S, Arndt G, Kaizer LK, Jensen T. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis. Metab Syndr Relat Disord. 2024 Oct; 22(8):608-618.
-
Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
-
Park J, Ntelis S, Yunasan E, Downton KD, Yip TC, Munir KM, Haq N. Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2023 12 21; 109(1):279-292.
-
Salahuddin T, Hebbe A, Daus M, Essien UR, Waldo SW, Rodriguez F, Ho PM, Simons C, Gilmartin HM, Doll JA. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021. Am Heart J. 2024 02; 268:68-79.
-
Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, Cohen RM, Crandall JP, Kahn SE, Krause-Steinrauf H, Larkin ME, Rasouli N, Tiktin M, Wexler DJ, Younes N. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022 09 22; 387(12):1063-1074.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|